Clinical Outcomes of Preservation Versus Resection of Portal/Superior Mesenteric Vein During Pancreaticoduodenectomy in Pancreatic Cancer Patients Who Respond to Neoadjuvant Treatment
There is a lack of evidence on the need to perform portal/superior mesenteric vein (PV/SMV) resection routinely in pancreatic ductal adenocarcinoma (PDAC) patients with venous involvement who responded to neoadjuvant treatment (NAT).
There is no significant differences in R0 rate, 5-year overall survival and recurrence-free survival between the PV/SMV preservation (PVP) group and PV/SMV resection (PVR) group.
PVP group showed significantly better 5-year PV/SMV stenosis free survival than the PVR group.
We propose that if dissection is possible and there is a high likelihood of achieving R0 resection after NAT, routine PVR may be unnecessary in PDAC patients with venous involvement.
Pancreatic head cancer patients who underwent surgery after neoadjuvant treatment between January 2012 and December 2022 at Seoul National University Hospital
Exclusion criteria
Metastatic unresectable and locally advanced pancreatic cancer
Resectable pancreatic cancer without portal/superior mesenteric vein invasion
Cancer aggravation after neoadjuvant treatment
Portal/superior mesenteric vein encasing and narrowing after neoadjuvant treatment
Patients who underwent palliative surgery
Non-pancreatic ductal adenocarcinoma patients
Patients who death within 30 days of surgery
Loss of follow-up patients
Patients who underwent resection for suspected main artery and adjacent organ invasion